Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Enveric Biosciences, Inc. (AMRH) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
10/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates"
09/27/2023 8-K Quarterly results
08/21/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program"
08/14/2023 8-K Quarterly results
Docs: "Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results"
07/24/2023 8-K Quarterly results
07/17/2023 8-K Quarterly results
06/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition"
06/06/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
05/24/2023 8-K Termination of a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointmen...
05/24/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Enveric Biosciences Receives Notice of Allowance from USPTO for C4-Carboxylic Acid-substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug"
05/19/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Enveric Biosciences to Participate in 2023 BIO International Convention in Boston"
05/18/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin"
04/03/2023 8-K Quarterly results
Docs: "Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results Key Highlights"
03/23/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1study of EB-373"
03/21/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications"
03/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery"
02/28/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Services to be Provided by Executive",
"Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635"
02/23/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635"
10/28/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
09/23/2022 8-K Changes in Registrant's Certifying Accountant  Interactive Data
09/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
09/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/01/2022 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
08/02/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/26/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "PRE-FUNDED COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Warrant Shares: _______ Issue Date: July 26, 2022 Initial Exercise Date: July 26, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Enveric Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and no...",
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Warrant Shares: _______ Issue Date: July 26, 2022 Initial Exercise Date: July 26, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Enveric Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and no...",
"PREFERRED INVESTMENT OPTION Enveric Biosciences, Inc. Preferred Investment Option Shares: ______ Issue Date: July 26, 2022 Initial Exercise Date: July 26, 2022 THIS PREFERRED INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on January 26, 2028 but not thereafter, to subscribe for and purchase from Enveric Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized...",
"PREFERRED INVESTMENT OPTION Enveric Biosciences, Inc. Preferred Investment Option Shares: ______ Issue Date: July 26, 2022 Initial Exercise Date: July 26, 2022 THIS PREFERRED INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on January 26, 2028 but not thereafter, to subscribe for and purchase from Enveric Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized...",
"PLACEMENT AGENT PREFERRED INVESTMENT OPTION Enveric Biosciences, Inc. Preferred Investment Option Shares: ______ Issue Date: July 26, 2022 Initial Exercise Date: July 26, 2022 THIS PLACEMENT AGENT PREFERRED INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on July 22, 2027 but not thereafter, to subscribe for and purchase from Enveric Biosciences, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2. This Pre...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of July 22, 2022, between Enveric Biosciences, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares and the Pre-Funded Warrants and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Preferred Investment Options, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of July 22, 2022, between Enveric Biosciences, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each...",
"SELLING SHAREHOLDERS The common stock being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to the selling shareholders, upon exercise of the warrants. For additional information regarding the issuances of those shares of common stock and warrants, see “Private Placement of Shares of Common Stock and Warrants” above. We are registering the shares of common stock in order to permit the selling shareholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock and the warrants, the selling shareholders have not had any material relationship with us within the past three years. The table below lists the selling shareholders and other information regarding the beneficial ownership...",
"Holder of Warrants to Purchase Common Stock"
07/19/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines Internationally Recognized Neuroscience Experts Will Work Closely with Enveric Scientists to Help Drive Clinical Innovation and Success CAMBRIDGE, MA, July 19, 2022 – Enveric Biosciences, Inc . , a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced the formation of its Scientific Advisory Board comprised of science and technology leaders, including globally renowned CNS and mental disorders experts, and chaired by Maurizio Fava, M.D. The SAB will advise Enveric on the Company’ s technology capabilities, innovation pipeline, early-stage candidate prioritization, and partnering..."
07/18/2022 8-K Appointed a new director
07/14/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy